German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Bloomberg noted, citing sources, that despite the market activity, no formal approaches have been made, and it is expected to be several months before any concrete interest emerges.German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.
据报道，德国药物开发公司Evotec SE（纳斯达克:EVO）在股价大幅下跌后正在咨询国防顾问，引发对公司易受收购的担忧。
Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company's drug pipeline and strategic value.
据报道，多家收购公司正在评估位于汉堡的Evotec作为潜在的收购目标，与顾问们进行初步讨论，评估该公司的药物管线和战略价值。
Evotec's shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from "buy" to "sell."
Evotec的股票大幅上涨，而之前的股价下跌了超过60％，股票最近一次跌至2017年3月以来的最低点。此次下跌是在Intron Health分析师将该股票评级从“买入”降至“卖出”之后发生的。
Bloomberg noted, citing sources, that despite the market activity, no formal approaches have been made, and it is expected to be several months before any concrete interest emerges.
彭博社援引消息人士称，尽管有市场活动，但尚未进行任何正式的接触，并预计需要几个月时间才会出现任何具体的兴趣。
The transition in leadership at Evotec adds another layer of complexity. In January, the company announced that CEO Werner Lanthaler would step down early for personal reasons. Subsequently, it was disclosed that Lanthaler had failed to report his stock trades on time, though this was unrelated to his departure.
Evotec领导层的变动增加了更多的复杂性。今年1月，该公司宣布首席执行官Werner Lanthaler因个人原因提前辞职。随后，披露Lanthaler未能及时报告他的股票交易，但这与他的离职无关。
Christian Wojczewski, the incoming CEO, will assume his role next month and is expected to review the situation before making any strategic decisions.
即将上任的首席执行官Christian Wojczewski预计将在下个月就目前的情况进行审查，之后再作出任何战略决策。
Major moves will require backing from Evotec's key shareholders, Novo Holdings A/S and Mubadala Investment Co. Novo Holdings is the parent company of drugmaker Novo Nordisk A/S (NYSE:NVO), indicating significant industry connections.
重大举措将需要Evotec的主要股东诺沃控股和穆巴达拉投资有限公司的支持。诺沃控股是药厂诺和诺德（纽交所:NVO）的母公司，这表明有重要的行业联系。
Evotec has established partnerships with major healthcare companies such as Bristol-Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co. (NYSE:LLY), focusing on developing treatments for chronic kidney disease, neuroscience, and metabolic disorders.
Evotec与布里斯托-迈尔斯斯奎布公司（纽交所:BMY）和礼来公司（纽交所:LLY）等主要医疗保健公司建立了合作伙伴关系，专注于开发治疗慢性肾脏疾病、神经科学和代谢性疾病的药物。
Most recently, Evotec said it made important scientific progress in its neuroscience collaboration with Bristol Myers Squibb, which triggered a research payment of $20 million to Evotec.
最近，Evotec表示，其与布里斯托-迈尔斯斯奎布的神经科学合作取得了重要的科学进展，引发了对Evotec的价值2000万美元的研究付款。
Price Action: EVO shares are up 9.09% at $4.44 at last check Thursday.
价格走势：EVO股票在周四的最后一次检查时上涨9.09％，至4.44美元。
Photo via Shutterstock
图片来自shutterstock。